— AFREZZA GUY (@Afrezzaguy) September 27, 2017
— vdexdiabetes (@vdexdiabetes) August 14, 2017
Just started using Afrezza with Tresiba. We now have an insulin we can inhale at each meal and works like IV insulin ultra rapid.
— Colette Nelson (@ColetteTYPE1) July 4, 2017
The Need for Faster Insulin: Problem Solved?
Journal of Diabetes Science and Technology 2017, Vol. 11(1) 157–159 / mannkindcorp.com
Considerable progress in treatment of diabetes has been made in the nearly 100 years following the discovery of insulin, and advances in insulin therapy have improved convenience, quality of life, overall glycemic control (A1C), and risk of hypoglycemia. An unmet need remains for a mealtime insulin that can faithfully reproduce the metabolic profile that ensues following meal ingestion in healthy persons. A number of “ultra-fast” insulin programs have been initiated, and Afrezza® (insulin human; Inhalation Powder, MannKind Corporation, Danbury, CT) stands as the first such product to be approved by the US FDA. Afrezza is unique as an “ultra-ultra” fast insulin, faster than any other entrant except IV insulin. The benefits and limitations of the Afrezza profile are discussed in this analysis.